TS
CYCN icon

Thomas Steyer’s Cyclerion Therapeutics CYCN Stock Holding History

Thomas Steyer’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,500
Closed -$952K – 107
2019
Q4 		$952K Sell
17,500
-1,331
-7% -$124K 0.01% 116
2019
Q3 		$4.57M Sell
18,831
-8,373
-31% -$1.81M 0.03% 90
2019
Q2 		$6.23M Buy
+27,204
New +$7.7M 0.04% 92

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Thomas Steyer's CYCN Position: Q1 2020 in Review

Thomas Steyer sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 17,500 shares — an estimated $952K sold.

Thomas Steyer first reported a position in CYCN in Q2 2019 and held it in 3 quarters. The position peaked at $6.23M in Q2 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

  • Thomas Steyer reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Thomas Steyer sold 17,500 Cyclerion Therapeutics shares in Q1 2020, an estimated $952K.
  • Thomas Steyer first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 3 quarters.
  • Thomas Steyer's Cyclerion Therapeutics position peaked at $6.23M in Q2 2019.
  • 80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.